Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Beijing Sun-Novo Pharmaceutical Research Yönetim

Yönetim kriter kontrolleri 2/4

Beijing Sun-Novo Pharmaceutical Research's CEO, Yujing Liu, Mar2020 tarihinde atandı, 4.25 yıl görev süresine sahiptir. , şirketin CN¥ 295.11M değerindeki 5.42% } hissesine doğrudan sahiptir. 295.11M. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 4.3 yıl ve 4.3 yıldır.

Anahtar bilgiler

Yujing Liu

İcra Kurulu Başkanı

n/a

Toplam tazminat

CEO maaş yüzdesi	n/a
CEO görev süresi	4.6yrs
CEO sahipliği	4.1%
Yönetim ortalama görev süresi	4.6yrs
Yönetim Kurulu ortalama görev süresi	4.6yrs

Son yönetim güncellemeleri

Recent updates

Concerns Surrounding Beijing Sun-Novo Pharmaceutical Research's (SHSE:688621) Performance

Sep 05

Market Still Lacking Some Conviction On Beijing Sun-Novo Pharmaceutical Research Co., Ltd. (SHSE:688621)

Jul 31

We Think Beijing Sun-Novo Pharmaceutical Research (SHSE:688621) Can Stay On Top Of Its Debt

May 29

CEO

Yujing Liu (42 yo)

4.6yrs

Görev süresi

CN¥1,950,000

Tazminat

Mr. Yujing Liu serves as Director and General Manager at Beijing Sun-Novo Pharmaceutical Research Co.,Ltd. since March 2020.

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Yujing Liu	GM & Director	4.6yrs	CN¥1.95m	4.06% CN¥ 198.2m
Lingyang Zhao	CFO, Board Secretary & Director	no data	CN¥1.25m	0.54% CN¥ 26.3m
Yan Shao	Deputy General Manager	4.6yrs	CN¥739.80k	2.25% CN¥ 109.7m
Xinquan Tuo	Deputy General Manager	4.6yrs	CN¥500.70k	2.25% CN¥ 109.9m
Guangtao Hao	Deputy GM & Core Technician	4.6yrs	CN¥873.70k	Veri yok
Huan Luo	Deputy GM & Core Technician	4.6yrs	CN¥935.00k	Veri yok
Weijun Yan	In Charge of Accounting	no data	Veri yok	Veri yok
Wang Mingjuan	Core Technical Staff	5.7yrs	CN¥452.10k	Veri yok
Xie Daosheng	Core Technical Staff	7.3yrs	CN¥917.00k	Veri yok
Yuanbo Li	Core Technical Staff	6.5yrs	CN¥795.40k	Veri yok
Gao Jian	Core Technical Staff	6.4yrs	CN¥355.30k	Veri yok

4.6yrs

Ortalama Görev Süresi

43.5yo

Ortalama Yaş

Deneyimli Yönetim: 688621 şirketinin yönetim ekibi, deneyimli ( 4.3 yıl ortalama görev süresi) olarak kabul edilir.

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Yujing Liu	GM & Director	4.6yrs	CN¥1.95m	4.06% CN¥ 198.2m
Lingyang Zhao	CFO, Board Secretary & Director	4.6yrs	CN¥1.25m	0.54% CN¥ 26.3m
Qiao Chen	Director	4.6yrs	Veri yok	Veri yok
Zhemin Shu	Independent Director	4.6yrs	CN¥60.00k	Veri yok
Zhuangkun He	Independent Director	4.6yrs	CN¥60.00k	Veri yok
Ying Zhang	Director	4.6yrs	Veri yok	Veri yok
Chen Li	Chairman of the Board	4.6yrs	CN¥1.33m	27.59% CN¥ 1.3b
Wenran Li	Director	4.6yrs	Veri yok	Veri yok
Dandan Wang	Chairman of the Supervisory Board	4.6yrs	Veri yok	Veri yok
Rong Item	Supervisor	4.6yrs	Veri yok	Veri yok
Jinfeng Zhang	Employee Representative Supervisor	4.6yrs	Veri yok	Veri yok

4.6yrs

Ortalama Görev Süresi

42yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: 688621's board of directors are considered experienced (4.6 years average tenure).

Beijing Sun-Novo Pharmaceutical Research Yönetim

Yönetim kriter kontrolleri 2/4

Anahtar bilgiler

Son yönetim güncellemeleri

Beijing Sun-Novo Pharmaceutical Research Co., Ltd., Annual General Meeting, May 16, 2024

Less than half of directors are independent

Less than half of directors are independent

Recent updates

New major risk - Share price stability

Beijing Sun-Novo Pharmaceutical Research Co., Ltd. to Report Q3, 2024 Results on Oct 29, 2024

Investor sentiment improves as stock rises 24%

Concerns Surrounding Beijing Sun-Novo Pharmaceutical Research's (SHSE:688621) Performance

Second quarter 2024 earnings released: EPS: CN¥0.68 (vs CN¥0.62 in 2Q 2023)

Investor sentiment deteriorates as stock falls 15%

Market Still Lacking Some Conviction On Beijing Sun-Novo Pharmaceutical Research Co., Ltd. (SHSE:688621)

Beijing Sun-Novo Pharmaceutical Research Co., Ltd. to Report First Half, 2024 Results on Aug 30, 2024

We Think Beijing Sun-Novo Pharmaceutical Research (SHSE:688621) Can Stay On Top Of Its Debt

First quarter 2024 earnings released: EPS: CN¥0.65 (vs CN¥0.43 in 1Q 2023)

Beijing Sun-Novo Pharmaceutical Research Co., Ltd., Annual General Meeting, May 16, 2024

Beijing Sun-Novo Pharmaceutical Research Co., Ltd. to Report Q1, 2024 Results on Apr 26, 2024

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Investor sentiment improves as stock rises 18%

Third quarter 2023 earnings released: EPS: CN¥0.48 (vs CN¥0.37 in 3Q 2022)

Beijing Sun-Novo Pharmaceutical Research Co., Ltd. (SHSE:688621) agreed to acquire the remaining 30% stake in Chengdu Sintanovo Biotechnology Co., Ltd. from Chengdu Shengpu Pharmaceutical Technology Center (Limited Partnership) for CNY 120 million.

New minor risk - Share price stability

Second quarter 2023 earnings released: EPS: CN¥0.62 (vs CN¥0.48 in 2Q 2022)

Beijing Sun-Novo Pharmaceutical Research Co., Ltd. to Report First Half, 2023 Results on Aug 29, 2023

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Less than half of directors are independent

Beijing Sun-Novo Pharmaceutical Research Co., Ltd. (SHSE:688621) agreed to acquire an unknown minority stake in Beijing Langyan Life Technology Holdings Co., Ltd. from Li Qian, Ganzhou Langyi Investment Center (Limited Partnership) and Liu Yujing.

Third quarter 2022 earnings released: EPS: CN¥0.52 (vs CN¥0.44 in 3Q 2021)

Investor sentiment improved over the past week

Second quarter 2022 earnings released: EPS: CN¥0.67 (vs CN¥0.64 in 2Q 2021)

Investor sentiment improved over the past week

First quarter 2022 earnings released: EPS: CN¥0.42 (vs CN¥0.34 in 1Q 2021)

Less than half of directors are independent

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Investor sentiment improved over the past week

CEO

Görev süresi

Tazminat

Liderlik Ekibi

Ortalama Görev Süresi

Ortalama Yaş

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş